A look at 6 key developments in advanced hematologic malignancies

A look at 6 IO products in the Heme space and what to watch out for.

June 10, 2021

Shipping the KRAS line

Update on the Novartis SHP2 inhibitor at ASCO21

June 8, 2021

Which early phase agents look promising – or not – ASCO21?

New product development and early phase anti-cancer agents have been very much a focus on BSB (and PSB…

June 6, 2021

Unheralded developments in renal cell carcinoma

A look at what's happening in RCC and what to watch out for at ASCO this year

June 4, 2021

Is olaparib scaling new heights in OlympiA?

PARP inhibitors move into the adjuvant setting at long last? Say it ain't so!

June 3, 2021

Advent of a new era in advanced prostate cancer treatment

A look at the first anti-cancer therapy with a radiopharmaceutical in advanced prostate cancer

June 3, 2021

ASCO21 Off the Beaten Track Part 2

A look at some hidden gems in the ASCO program and what it all means in terms of the science.

May 27, 2021

Off the Beaten ASCO21 Track Part 1

Hidden early stage gems to watch out for at ASCO21

May 25, 2021

Highlights and lowlights from the ASCO21 data drop

Which abstracts stood out in the initial run through of the data? Includes some hidden gems and surprises!

May 20, 2021

A twist in the IO tail

Going beyond the obvious conclusion with anti-LAG3 therapy

May 19, 2021

When PARP and immunotherapy worlds collide

New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.

May 12, 2021

The future of breast cancer research

Some key learnings from the ESMO Breast Cancer meeting held last week

May 10, 2021

Tooting the DDR horn

Bridging the DDR gap from AACR to ASCO

May 7, 2021